Annals of Surgical Oncology

, Volume 20, Issue 10, pp 3279–3285 | Cite as

Treatment Efficacy with Accelerated Partial Breast Irradiation (APBI): Final Analysis of the American Society of Breast Surgeons MammoSite® Breast Brachytherapy Registry Trial

  • Chirag ShahEmail author
  • Shahed Badiyan
  • J. Ben Wilkinson
  • Frank Vicini
  • Peter Beitsch
  • Martin Keisch
  • Douglas Arthur
  • Maureen Lyden
Breast Oncology



The purpose of this study was to examine data on treatment efficacy, cosmesis and toxicities for the final analysis of the American Society of Breast Surgeons MammoSite® breast brachytherapy registry trial.


A total of 1,449 cases of early-stage breast cancer underwent breast conserving therapy. The single-lumen MammoSite® device was used to deliver accelerated partial breast irradiation (APBI) (34 Gy in 3.4 Gy fractions). Of these, 1,255 cases (87 %) had invasive breast cancer (IBC) and 194 cases had DCIS. Median follow-up was 63.1 months with 45 % of all patients having follow-up of 6 years or longer.


There were 41 cases (2.8 %) that developed an ipsilateral breast tumor recurrence (IBTR) for a 5-year actuarial rate of 3.8 % (3.7 % for IBC and 4.1 % for DCIS). Tumor size (odds ratio [OR] = 1.1, p = 0.03) and estrogen receptor negativity (OR = 3.0, p = 0.0009) were associated with IBTR, while a trend was noted for positive margins (OR = 2.0, p = 0.06) and cautionary/unsuitable status compared with suitable status (OR = 1.8, p = 0.07). The percentage of patients with excellent/good cosmetic results at 60, 72, and 84 months was 91.3, 90.5, and 90.6 %, respectively. The overall rates of fat necrosis and infections remained low at 2.5 and 9.6 % with few late toxicity events beyond 2 years. The overall symptomatic seroma rate was 13.4 and 0.6 % beyond 2 years.


The final analysis of treatment efficacy, cosmesis, and toxicity from the American Society of Breast Surgeons MammoSite® breast brachytherapy registry trial confirms previously noted excellent results and compares favorably with other forms of APBI with similar follow-up and to outcomes seen in selected patients treated with whole breast irradiation.


Breast Conserve Therapy Accelerate Partial Breast Irradiation Ipsilateral Breast Tumor Recurrence Estrogen Receptor Negativity Whole Breast Irradiation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The MammoSite® breast brachytherapy registry trial was supported in part by a Grant by Hologic, Inc., Bedford, MA. Hologic, Inc. had no access to or influence on the data, analysis, or conclusions of this paper prior to publication.

Conflict of interest

There are no conflicts of interest to declare except Martin Keisch, M.D.: Consultant/Advisory Board, Hologic, Inc., Bedford, Massachusetts.


  1. 1.
    Smith BD, Arthur DW, Buchholz TA, Haffty BG, Hahn CA, Hardenbergh PH, et al. Accelerated partial breast irradiation consensus statement from the American Society for Radiation Oncology (ASTRO). Int J Radiat Oncol Biol Phys. 2009;74:987–1001.PubMedCrossRefGoogle Scholar
  2. 2.
    Shah C, Antonucci JV, Wilkinson JB, Wallace M, Ghilezan M, Chen P, et al. Twelve-year clinical outcomes and patterns of failure with accelerated partial breast irradiation versus whole-breast irradiation: results of a matched-pair analysis. Radiother Oncol. 2011;100:210–4.PubMedCrossRefGoogle Scholar
  3. 3.
    Polgar C, Fodor J, Major T, Nemeth G, Lovey K, Orosz Z, et al. Breast-conserving treatment with partial or whole breast irradiation for low-risk invasive breast carcinoma- 5-year results of a randomized trial. Int J Radiat Oncol Biol Phys. 2007;69:694–702.PubMedCrossRefGoogle Scholar
  4. 4.
    Smith GL, Xu Y, Buchholz TA, Giordano SH, Jiang J, Shih YC, et al. Associations between treatment with brachytherapy versus whole-breast irradiation and subsequent mastectomy, complications, and survival among older women with invasive breast cancer. J Am Med Assoc. 2012;307:1827–37.CrossRefGoogle Scholar
  5. 5.
    Presley CJ, Soulos PR, Herrin J, Roberts KB, Yu JB, Killelea B, et al. Patterns of use and short-term complications of breast brachytherapy in the national Medicare population from 2008–2009. J Clin Oncol. 2012;30:4302–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Benitez PR, Keisch ME, Vicini F, Stolier A, Scroggins T, Walker A, et al. Five-year results: the initial clinical trial of MammoSite balloon brachytherapy for partial breast irradiation in early-stage breast cancer. Am J Surg. 2007;194:456–62.PubMedCrossRefGoogle Scholar
  7. 7.
    Keisch M, Vicini F, Kuske RR, Hebert M, White J, Quiet C, et al. Initial clinical experience with the MammoSite breast brachytherapy applicator in women with early-stage breast cancer treated with breast-conserving therapy. Int J Radiat Oncol Biol Phys. 2003;55:289–93.PubMedCrossRefGoogle Scholar
  8. 8.
    Shaitelman SF, Vicini FA, Beitsch P, Haffty B, Keisch M, Lyden M. Five-year outcome of patients classified using the American Society for Radiation Oncology consensus statement guidelines for the application of accelerated partial breast irradiation: an analysis of patients treated on the American Society of Breast Surgeons MammoSite Registry Trial. Cancer. 2010;116:4677–85.PubMedCrossRefGoogle Scholar
  9. 9.
    Recht A, Silver B, Schnitt S, Connolly J, Hellman S, Harris JR. Breast relapse following primary radiation therapy for early breast cancer. I. Classification, frequency and salvage. Int J Radiat Oncol Biol Phys. 1985;11:1271–6.PubMedCrossRefGoogle Scholar
  10. 10.
    Rose MA, Olivotto I, Cady B, Koufman C, Osteen R, Silver B, et al. Conservative surgery and radiation therapy for early breast cancer. Long-term cosmetic results. Arch Surg. 1989;124:153–7.PubMedCrossRefGoogle Scholar
  11. 11.
    Hattangadi JA, Taback N, Neville B, Harris JR, Punglia RS. Accelerated partial breast irradiation using brachytherapy for breast cancer: patterns in utilization and guideline accordance. J Natl Cancer Inst. 2012;104:29–41.PubMedCrossRefGoogle Scholar
  12. 12.
    Fisher B, Anderson S, Bryant J, Margolese RG, Deutsch M, Fisher ER, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med. 2002;347:1233–41.PubMedCrossRefGoogle Scholar
  13. 13.
    van Dongen JA, Voogd AC, Fentiman IS, Legrand C, Sylvester RJ, Tong D, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst. 2000;92:1143–50.PubMedCrossRefGoogle Scholar
  14. 14.
    Hughes KS, Schnaper LA, Berry D, Cirrincione C, McCormick B, Shank B, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;35:971–7.CrossRefGoogle Scholar
  15. 15.
    White JR, Winter KA, Kuske RA, et al. Long-term outcome from RTOG 9517: a phase I/II study of accelerated partial breast irradiation (APBI) with multicatheter brachytherapy (MCT) following lumpectomy for early-stage breast cancer. J Clin Oncol 2012;30:147.CrossRefGoogle Scholar
  16. 16.
    Vaidya JS, et al Targeted intraoperative radiotherapy for early breast cancer: TARGIT-a trial-updated analysis of local recurrence and first analysis of survival. SABCS. 2012; Abstract S4-2.Google Scholar
  17. 17.
    Orecchia R. Eliot trials in Milan: results. Radiother Oncol. 2012;103: S4.CrossRefGoogle Scholar
  18. 18.
    Indelicato D, Grobmyer SR, Newlin H, Morris CG, Haigh LS, Copeland EM 3rd, et al. Association between operative closure type and acute infection, local recurrence, and disease surveillance in patients undergoing breast conserving therapy for early-stage breast cancer. Surgery. 2007;141:645–53.PubMedCrossRefGoogle Scholar
  19. 19.
    Monticciolo DL, Biggs K, Gist AK, Sincleair ST, Hajdik RL, Nipper ML, et al. Breast conserving therapy with accelerated partial breast versus external beam whole breast irradiation: comparison of imaging sequela and complications in a matched population. Breast J. 2011;17:187–90.PubMedCrossRefGoogle Scholar
  20. 20.
    Cuttino LW, Todor D, Rosu M, Arthur DW. Skin and chest wall dose with multi-catheter and MammoSite breast brachytherapy: implications for late toxicity. Brachytherapy. 2009;8:223–6.PubMedCrossRefGoogle Scholar

Copyright information

© Society of Surgical Oncology 2013

Authors and Affiliations

  • Chirag Shah
    • 1
    Email author
  • Shahed Badiyan
    • 1
  • J. Ben Wilkinson
    • 2
  • Frank Vicini
    • 3
  • Peter Beitsch
    • 4
  • Martin Keisch
    • 5
  • Douglas Arthur
    • 6
  • Maureen Lyden
    • 7
  1. 1.Department of Radiation OncologySumma Health SystemAkronUSA
  2. 2.Department of Radiation OncologyOakland University William Beaumont School of MedicineRoyal OakUSA
  3. 3.Michigan Healthcare Professionals/21st Century OncologyFarmington HillsUSA
  4. 4.Dallas Surgical GroupDallasUSA
  5. 5.Cancer HealthCare AssociatesUniversity of Miami HospitalMiamiUSA
  6. 6.Department of Radiation Oncology, Massey Cancer CenterVirginia Commonwealth UniversityRichmondUSA
  7. 7.Biostat International, IncTampaUSA

Personalised recommendations